Trifluoroacetic Acid

Trifluoroacetic Acid

SCHEMBL3337473

CC(C)CCNCCc1cccc(-c2ccc(C(N)=O)cc2)c1.O=C(O)C(F)(F)F

nearest known ligand 0.44

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC1 Q13547 1/20 0.44
NPC1 O15118 1/20 0.44
RAB9A P51151 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
AOC3 Q16853 2/20 0.43
PDE4A P27815 2/20 0.42
PDE4B Q07343 2/20 0.42
PDE4C Q08493 2/20 0.42
PDE4D Q08499 2/20 0.42
CTSS P25774 1/20 0.42
CTSK P43235 1/20 0.42
F10 P00742 1/20 0.41
F7 P08709 1/20 0.41
F3 P13726 1/20 0.41
DPP4 P27487 2/20 0.41
DPP8 Q6V1X1 1/20 0.41
DPP9 Q86TI2 1/20 0.41
DPP7 Q9UHL4 1/20 0.41
SLC2A1 P11166 1/20 0.41
RORC P51449 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Trifluoroacetic Acid SCHEMBL16194886 0.93 DPP4 (0.44) HDAC1F10F7F3DPP4
SCHEMBL12651062 0.92 AOC3 (0.49) HDAC1NPC1RAB9ASMN1; SMN2AOC3
Trifluoroacetic Acid SCHEMBL3345691 0.91 HDAC1 (0.52) HDAC1NPC1RAB9ASMN1; SMN2AOC3
SCHEMBL12651258 0.84 FAAH (0.43) HDAC1NPC1RAB9ASMN1; SMN2AOC3
SCHEMBL12607892 0.82 HDAC1 (0.55) HDAC1NPC1RAB9ASMN1; SMN2AOC3
Trifluoroacetic Acid SCHEMBL3342436 0.82 HDAC1 (0.54) HDAC1NPC1RAB9ASMN1; SMN2F10
Trifluoroacetic Acid SCHEMBL3339548 0.80 MEN1 (0.43) AOC3F10SLC2A1HTR5AOPRM1
SCHEMBL12607660 0.76 CHEK2 (0.50) HDAC1NPC1RAB9ASMN1; SMN2CTSS
Trifluoroacetic Acid SCHEMBL3341972 0.75 HTR5A (0.58) HDAC1HTR5AOPRM1OPRD1OPRK1
SCHEMBL3236652 0.75 PARP10 (0.55) NPC1RAB9ASMN1; SMN2OPRM1OPRD1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140323487-A1 Novel Compounds As Antagonists Or Inverse Agonists At Opioid Receptors GLAXOSMITHKLINE LLC 2014-10-30 US disclosed
US-20100113512-A1 METHOD OF TREATMENT USING NOVEL ANTAGONISTS OR INVERSE AGONISTS AT OPIOID RECEPTORS IGNAR DIANE MICHELE 2010-05-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100113512-A1 METHOD OF TREATMENT USING NOVEL ANTAGONISTS OR INVERSE AGONISTS AT OPIOID RECEPTORS OPRL1, OPRD1, OPRK1 HDAC1 1478/4885NPC1 3112/4885RAB9A 2340/4885
US-20140323487-A1 Novel Compounds As Antagonists Or Inverse Agonists At Opioid Receptors OPRL1, OPRM1, OPRK1 HDAC1 2440/4885NPC1 3467/4885RAB9A 1186/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.